-
Product Pipeline
Zealand's Pipeline comprises 1 compound in ph 3, 1 in ph 2, 3 in ph 1, and 2 in pre-clinical develop...
-
2010
8 Marts 2010:Press Release no. 2, 2010: Zealand Pharma Announces Augmentation of its Management...
Product Pipeline
Zealand's Pipeline comprises 1 compound in phase III, 1 compound in phase II, 3 compounds in phase I, and 2 compounds in pre-clinical development.
The development of Rotigaptide (ZP123, GAP-486) for arrhythmia (licensed to Wyeth) and of ZP120 for acute heart failure has been terminated after Phase II clinical trials. The development of ZP2435 for treatment of obesity was terminated in preclinical development.
The following table summarizes the status of Zealand Pharma's current product pipeline.
|
Product Candidate |
Indication |
Commercial Partner |
Status |
|
Phase III - initialized 2008. |
|||
|
Post-surgical Organ Failure |
Action Pharma |
Phase II – Initiated in 2008 |
|
|
Phase I – single dose, safety and tolerability trial. Finalized 2008 |
|||
|
Phase I – single dose, safety and tolerability trial initiated October 2007 |
|||
|
|
Phase I – single dose, safety and tolerability trial initiated January 2009 |
||
|
|
Preclinical |
||
|
|
Preclinical |
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.